The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...

Vertex Pharmaceuticals announced that Journavx will be priced at $15.50 per pill.The FDA-approved medication, available as a 50-milligram prescription tablet taken every 12 hours, offers a non ...

FDA approves Journavx, the first new painkiller in over two decades. The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

FDA Approves New Non-Opioid Painkiller, Journavx: 'No Addiction Potential' A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous By ...

The FDA's approval process for Journavx included an evaluation of its safety and efficacy. Clinical trials demonstrated that the drug is effective in managing acute pain without the adverse ...

FDA approves Journavx, the first new painkiller in over two decades. The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

FDA approves Journavx, the first new painkiller in over two decades. The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

FDA approves Journavx, the first new painkiller in over two decades. The new pain pill is designed to eliminate risks of addiction and overdose but it's more expensive than opioids and may be less ...